MOG-antibody associated disease

THURSDAY, 7 MARCH 2019

08.30 - 08.45 Welcome from ECTRIMS President
B. Hemmer (Munich, DE)

08.45 - 09.00 Introduction – State of the art / unmet needs
S. Vukusic (Lyon, FR)

09.00 - 10.15 Session 1: From immunology to pathology of MOG-Ab associated disease
Chair persons: C. Lucchinetti (Rochester, US), F. Brilot (Sydney, AU)

09.00 History and update on the detection methods
M. Reindl (Innsbruck, AT)

09.15 Animal models of MOG autoimmunity
E. Meinl (Munich, DE)

09.30 Imaging the in vivo effects of human MOG antibodies
B. Hemmer (Munich, DE)

09.45 Pathology of MOG-Ab associated disease
H. Lassmann (Vienna, AT)

10.00 Which pieces are missing in our understanding of MOG-Ab associated disease?
T. Derfuss (Basel, CH)

10.15 - 10.45 Coffee break

10.45 - 11.30 Roundtable/Panel discussion 1

11.30 - 12.45 Session 2: The clinical spectrum and prognosis of MOG-Ab associated disease
Chair persons: S. Pittock (Rochester, US), M. I. Leite (Oxford, UK)

11.30 Prevalence of MOG-Ab (Control donors/ NMO spectrum / children / before onset, different countries)
J. De Sèze (Strasbourg, F)
11.45 Typical spectrum in adults
A.-K. Pröbstel (San Francisco, US)

12.00 Typical spectrum in children
K. Deiva (Paris, FR)

12.15 Atypical presentations
K. Fujihara (Fukushima, JP)

12.30 Clinical unmet needs (cognition, vaccination, pregnancy...)
M.P. Amato (Florence, IT)

12.45 - 14.00 Lunch

14.00 - 14.45 Session 2: The clinical spectrum and prognosis of MOG-Ab associated disease (continued)
Chair persons: S. Pittock (Rochester, US), M. I. Leite (Oxford, UK)

14.00 Prognosis in adults
H.J. Kim (Goyang, KR)

14.15 Prognosis in children
T. Chitnis (Boston, USA)

14.30 Are MOG-Ab a disease biomarker?
P. Waters (Oxford, UK)

14.45 – 15.30 Roundtable/Panel discussion 2

15.30 - 16.00 Coffee break

16.00 - 17.15 Session 3: Non clinical evaluation of MOG-Ad associated disorder
Chair persons: A. Traboulsee (Vancouver, CA), A. Petzold (London, UK)

16.00 CSF immunology of MOG-Ab associated disease
S. Jarius (Heidelberg, DE)

16.15 Exploring the visual pathways (OCT-MRI)
F. Paul (Berlin, DE)

16.30 Conventional brain MRI
J. Palace (Oxford, UK)
16.45 Conventional spinal Cord MRI
   D. Sato (Porto Alegre, BR)

17.00 Unmet needs (advance and future of imaging MOG)
   O. Ciccarelli (London, UK)

17.15 - 18.00 Roundtable/Panel discussion 3

18.00 - 18.15 Wrap-up Day 1
   T. Derfuss (Basel, CH)

19.15 ECTRIMS Focused Workshop Dinner

FRIDAY, 8 MARCH 2019

08.30 - 10.00 Session 4: How should we treat MOG-Ab associated disease
   Chair persons: B. Weinshenker (Rochester, US), R. Hintzen (Rotterdam, NL)

08.30 Attacks
   I. Kleiter (Bochum, DE)

08.45 Immediately after the 1st episode - YES
   M. Tintore (Barcelona, ES)

09.00 Immediately after the 1st episode - NO
   E. Waubant (San Francisco, US)

09.15 With MS disease-modifying treatment
   R. Marignier (Lyon, FR)

09.30 With NMO treatment
   A. Jacob (Liverpool, UK)

09.45 Treatment unmet needs (evaluation of treatment - trial design)
   B. Weinshenker (Rochester, US)

10.00 - 10.45 Roundtable/Panel discussion 4

10.45 - 11.15 Coffee break
11.15 - 12.00       Meeting summary
                      Session 1: B. Hemmer (Munich, DE)
                      Session 2: S. Vukusic (Lyon, FR)
                      Session 3: T. Derfuss (Basel, CH)
                      Session 4: R. Marignier (Lyon, FR)

12.00 - 13.00       Roundtable/Panel discussion 5

13.00       End of the workshop / Lunch and individual departure